| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7767429 | HALOZYME THERAP | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
Sep, 2027
(3 years from now) | |
Hylenex Recombinant is owned by Halozyme Therap.
Hylenex Recombinant contains Hyaluronidase Recombinant Human.
Hylenex Recombinant has a total of 1 drug patent out of which 0 drug patents have expired.
Hylenex Recombinant was authorised for market use on 02 December, 2005.
Hylenex Recombinant is available in injectable;injection dosage forms.
The generics of Hylenex Recombinant are possible to be released after 23 September, 2027.
Drugs and Companies using HYALURONIDASE RECOMBINANT HUMAN ingredient
Market Authorisation Date: 02 December, 2005
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
HYLENEX RECOMBINANT family patents
